Browse hierarchy: [Obstetrics/Gynecology (OB)](/submissions/OB) → [Subpart E — Surgical Devices](/submissions/OB/subpart-e%E2%80%94surgical-devices) → [21 CFR 876.4310](/submissions/OB/subpart-e%E2%80%94surgical-devices/876.4310) → QAG — Endoscopic Electrosurgical Clip Cutting System

# QAG · Endoscopic Electrosurgical Clip Cutting System

_Obstetrics/Gynecology · 21 CFR 876.4310 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/OB/subpart-e%E2%80%94surgical-devices/QAG

## Overview

- **Product Code:** QAG
- **Device Name:** Endoscopic Electrosurgical Clip Cutting System
- **Regulation:** [21 CFR 876.4310](/submissions/OB/subpart-e%E2%80%94surgical-devices/876.4310)
- **Device Class:** 2
- **Review Panel:** [Obstetrics/Gynecology](/submissions/OB)

## Identification

An endoscopic electrosurgical clip cutting system is a prescription device that applies electrical energy to fragment metallic clips, which are devices placed in the digestive tract to close gastrointestinal perforations, hemorrhages, or perform resection. The system includes instruments that are then used to remove the fragmented clips from the digestive tract.

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the FD&C Act, the endoscopic electrosurgical clip cutting system is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Performance bench testing to evaluate the functionality (including stress, compatibility, usability, and reliability) of the device during use;
(ii) Electrical and thermal safety testing; and
(iii) Electromagnetic compatibility testing.
(2) Animal testing must evaluate tissue damage, including thermal effects, during the clip removal procedure. This testing must also evaluate usability and effectiveness of the device.
(3) The patient-contacting components of the device must be demonstrated to be biocompatible.
(4) Performance data must demonstrate the sterility of the device components intended to be provided sterile.
(5) Performance data must support shelf life by demonstrating continued sterility of the device (or the sterile components), package integrity, and device functionality over the labeled shelf life.
(6) Labeling of the device must include:
(i) Instructions for use, and
(ii) A shelf life for single use components.

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN160014](https://fda.innolitics.com/submissions/OB/subpart-e%E2%80%94surgical-devices/QAG/DEN160014.md) | remOVE System | Ovesco Endoscopy AG | Dec 22, 2017 | DENG |

## Top Applicants

- Ovesco Endoscopy AG — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/OB/subpart-e%E2%80%94surgical-devices/QAG](https://fda.innolitics.com/submissions/OB/subpart-e%E2%80%94surgical-devices/QAG)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com